[A13-36] Aflibercept (Eylea) extension of approval - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Last updated 02.01.2014
Project no.:
A13-36
Commission:
Commission awarded on 24.09.2013 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A15-49 | Aflibercept (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-11 | Aflibercept (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A14-32 | Aflibercept (extension of approval) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A13-08 | Aflibercept (Zaltrap) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-19 | Aflibercept - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2014-03-20 A G-BA decision was published.